Beta-blockers for the treatment of hypertension in patients with diabetes: Exploring the contraindication myth

Cardiovascular Drugs and Therapy

Volumn 13, Issue 5, 1999, Pages 435-439

  Majumdar, Sumit R ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Department of Ambulatory Care ^*  (United States)

Author keywords

Beta blockers; Diabetes mellitus; Guidelines; Hypertension; Treatment

Indexed keywords

ACEBUTOLOL; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LABETALOL; LIPID; METOPROLOL; NISOLDIPINE; TIMOLOL;

ARTICLE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INSULIN RESISTANCE; KIDNEY DISEASE; KIDNEY PARENCHYMA; LIPID BLOOD LEVEL; MEDICAL LITERATURE; PRIORITY JOURNAL; SECONDARY PREVENTION;

ADRENERGIC BETA-ANTAGONISTS; DIABETES COMPLICATIONS; HUMANS; HYPERTENSION; HYPOGLYCEMIA; INSULIN RESISTANCE;

EID: 0032872663     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007860108024     Document Type: Article

References (43)

1. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992;19:403-418.
2. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: The Framingham Study. Circulation 1979;59:8-13.
3. Statement on hypertension in diabetes mellitus: Final report. Arch Int Med 1987;147:830-842.
4. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: A systematic review and meta-analysis. JAMA 1997;277:739-745.
5. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996;276:1886-1892.
6. Klein R, Moss SE, Klein BE and Demets DL. Relation of ocular and systemic factors to survival in diabetes. Arch Int Med 1989; 149:266-272.
7. Warrant JH, Laffel LMB, Valsania P, Chrislieb AR, Krolewski AS. Excess mortality associated with diuretic therapy in diabetes mellitus. Arch Int Med 1991;151: 1350-1356.
8. Myers MG, Carruthers SG, Leenen FHH, et al. Recommendations from the Canadian Hypertension Society Consensus Conference on the pharmacologic treatment of hypertension. Can Med Assoc J 1989;140:1141-1146.
9. Physicians Desk Reference, 50th Ed, Medical Economics Data Production Company, 1996.
10. Kaplan NM. Clinical Hypertension, 6th Ed. Williams and Wilkins, 1994: chapter 7.
11. Leese GP, Savage MW, Chattington PD, Vora JR The diabetic patient with hypertension. Postgrad Med J 1996;72: 263-268.
12. National High Blood Pressure Expert Panel Working Group. Hypertension in diabetes. Hypertension 1994;23: 147-162.
13. Kaplan NM, Rosenstock J, Raskin P. A differing view of treatment of hypertension in patients with diabetes mellitus. Arch Int Med 1987;147:1160-1162.
14. Sowers JR, Zemel MB. Clinical implications of hypertension in the diabetic patient. Am J Hyper 1990;3:415-424.
15. Molnar GW, Read RC, Wright FE. Propranolol enhancement of hypoglycemic sweating. Clin Pharmacol Ther 1974: 15:490-496.
16. Giugliano D, Acampora R. Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin dependent diabetes mellitus and hypertension: A randomized controlled trial. Ann Intern Med 1997;126:955-959.
17. Lager T, Blohme G, Smith U. Effects of cardioselective and non-selective beta blockade on the hypoglycemic response in insulin dependent diabetes. Lancet 1979;1:458-462.
18. Herings RM, de Boer A, Striker BH, Leufkens HG, Porsius A. Hypoglycemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 1995;345:1195-1198.
19. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 1997;278:40-43.
20. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvaseular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713-720.
21. Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nophropathy-an update. Hypertension 1995;26:869-879.
22. Manolio TA, Cutler JA, Furberg CD, et al. Trends in pharmacologic management of hypertension in the United States. Arch Int Med 1995; 155:829-837.
23. Jonas M, Reicher-Reiss H, Boyko V, et al. Usefulness of beta blocker therapy in patients with non-insulin dependent diabetes mellitus and coronary artery disease. Am J Cardiol 1996;77:1273-1277.
24. Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122:133-141.
25. Lasser NL, Grandits G, Caggiula AW, et al. Effects of antihypertensive therapy on plasma lipids and lipoproteins in the Multiple Risk Factor Intervention Trial. Am J Med 1984;76(2A):52-66.
26. Samuelsson O, Hedner T, Person B, et al. The vole of diabetes mollitus and hypertriglyceridemia as coronary risk factors in treated hypertension: 15 years of follow- up of antihypertensive treatment in middle aged men in the Primary Prevention Trial in Goteborg, Sweden. J Int Med 1994; 235:217-227.
27. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-2444.
28. Yusuf S Peto R, Lewis JA, Collins R, Sleight P. Beta blockade during and after myocardial infarction: a review of the randomized controlled trials. Prog Cardiovase Dis 1987;27: 335-343.
29. Byington RP, Worthy J, Craven T, Furberg CD. Propranolol-induced changes and their prognostic significance after myocardial infarction: The Beta-Blocker Heart Attack Trial experience. Am J Cardiol 1990;65:1287-1291.
30. Gundersen T, Kuekshus J. Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care 1983;6: 285-290.
31. Fleming TR, Demets DL. Surrogate endpoints in clinical trials: Are we being misled? Ann Intern Med 1996;125:605-613.
32. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-788.
33. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nislodipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998;338:645-652.
34. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;74:620-625.
35. Furberg CD, Psaty BM, Meyer JV. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-1331.
36. Borhani NO, Mereuri M, Borhani PA, et al Final outcome results of the Multicentre Isradipine Diuretic Atherosclerosis Study (MIDAS): A randomized controlled trial. JAMA 1996;76:785-791.
37. Tatti P, Pahor M, Byington RF, DiMauro P, Guarisco R, Strollo F. Results of the Fosinopril Amlodipine Cardiovascular Events Trial (FACET) in hypertensive patients with non-insulin dependent diabetes mellitus (NIDDM). Circulation 1997;96(Suppl I):1764.
38. De Bono G, Kaye CM, Roland E, Summers AJH. Acebutolol: Ten years of experience. Am Heart J 1995;109:1211-1223.
39. Boissel JP, Leizorovicz A, Piclolet H, et al. Secondary prevention after high-risk acute myocardial infarction with low dose acebutolol. Am J Cardiol 1990;66:251-260.
40. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.
41. Maschio G, Alberti D, Janin G, et al, Effect of the angiotensin converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334:930-945.
42. Sawicki PT. Do ACE inhibitors offer specific benefits in the antihypertensive treatment of diabetic patients? 17 years of unfulfilled promises. Diabetologia 1998;41:598-602.
43. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: A meta-analysis of randomized controlled trials. Arch Intern Med 1991;151:1769-1776.